CD79A Antibody (ZL7-4): sc-13529

CD79A Antibody (ZL7-4) is a mouse monoclonal IgG1 antibody that detects CD79A in human samples through applications such as immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). CD79A, also known as MB-1, is a crucial component of the B cell antigen receptor complex, functioning alongside CD79B to facilitate the signaling necessary for B cell activation and development. CD79A on the surface of B cells is essential for effective presentation of antigens, as CD79A associates with membrane immunoglobulins like IgM and IgD, enabling these immunoglobulins to achieve surface expression. This interaction is vital for initiating the immune response, as CD79A′s cytoplasmic tail contains an immuno-receptor tyrosine-based activation motif (ITAM) that is instrumental in recruiting and activating tyrosine kinases, which in turn propagate the signaling cascade necessary for B cell activation. CD79A′s ability to mediate these critical processes underscores CD79A′s importance in both adaptive immunity and the development of B cell malignancies, making CD79A (ZL7-4) antibody an invaluable tool for researchers studying B cell function and related pathologies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD79A Antibody (ZL7-4) References:

1. Alternative splicing of CD79a (Ig alpha) and CD79b (Ig beta) transcripts in human B-CLL cells.  |  Alfarano, A., et al. 1999. Curr Top Microbiol Immunol. 246: 241-6; discussion 247-8. PMID: 10396062
2. CD79a(+) T-cell lymphoblastic lymphoma with coexisting Langerhans cell histiocytosis.  |  Li, S. and Borowitz, MJ. 2001. Arch Pathol Lab Med. 125: 958-60. PMID: 11419987
3. Clinicopathological significance of CD79a expression in classic Hodgkin lymphoma.  |  Sakatani, A., et al. 2020. J Clin Exp Hematop. 60: 78-86. PMID: 32641598
4. CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia.  |  Lenk, L., et al. 2021. Commun Biol. 4: 73. PMID: 33452446
5. Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.  |  Julamanee, J., et al. 2021. Mol Ther. 29: 2677-2690. PMID: 33940156
6. Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy.  |  Chen, M., et al. 2022. Leuk Lymphoma. 63: 426-434. PMID: 34672246
7. Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression.  |  Huse, K., et al. 2022. J Immunol. 209: 2042-2053. PMID: 36426942
8. Mechanism of cystogenesis by Cd79a-driven, conditional mTOR activation in developing mouse nephrons.  |  Tran Nguyen Truc, L., et al. 2023. Sci Rep. 13: 508. PMID: 36627370
9. B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ (CD79b) in Normal and Malignant B Cells.  |  Tkachenko, A., et al. 2023. Int J Mol Sci. 25: PMID: 38203179
10. Fluoxetine Successfully Treats Intracranial Enterovirus E18 Infection in a Patient with CD79a Deficiency Arising from Segmental Uniparental Disomy of Chromosome 19.  |  Yu, L., et al. 2024. J Clin Immunol. 44: 137. PMID: 38805163

The preferred CD79A antibody is CD79A Antibody (HM47): sc-20064.